Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71885 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 27.04.2026. Verfasst von Jiayin Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hebei Natural Science Foundation, Wu Jieping Medical Foundation, Natural Science Foundation of Hebei Province.
Abstract (Originalsprache)
Given the limited evidence on prognostic factors specifically for older patients with extensive‐stage small cell lung cancer (ES‐SCLC), a population with distinct clinical characteristics, this study aimed to validate whether previously reported prognostic indicators retain their predictive value in this vulnerable group. A retrospective analysis was conducted on data from 270 older ES‐SCLC patients who received treatment at the Fourth Hospital of Hebei Medical University between December 2016 and June 2024. By the final follow‐up date of October 15, 2024, 212 deaths had been recorded. The median progression‐free survival (mPFS) was 6.7 months (95% confidence interval [CI] 6.0–7.4), and the median overall survival (mOS) was 13.1 months (95% CI 11.8–14.4). For PFS, univariate and multivariate Cox analyses identified first‐line chemotherapy (CT) and old‐old (≥ 75 years) as independent adverse prognostic factors. For OS, old‐old, a positive smoking history, bone metastasis, and high‐lactate dehydrogenase (> 250 U/L) were identified as significant adverse prognostic factors. Notably, high‐pro‐gastrin‐releasing peptide (ProGRP) (> 69.2 pg/mL) was significantly associated with an increased risk of death during the follow‐up period beyond 10 months (HR = 1.85, 95% CI 1.05–3.26, p = 0.032); conversely, no significant association was observed within the initial 10 months of follow‐up (HR = 0.84, 95% CI 0.44–1.60, p = 0.604). In conclusion, these findings not only corroborate the prognostic value of previously identified risk factors in older patients with ES‐SCLC but also demonstrate that the prognostic impact of ProGRP is distinctly time‐dependent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Cangzhou Central Hospital, Cangzhou, Hebei, China.
ORCID-Profile: Yan Liu, Yudong Wang
Förderung
- Hebei Natural Science Foundation
- Wu Jieping Medical Foundation
- Natural Science Foundation of Hebei Province
Zitieren
APA
Liu, J., Liu, X., Li, X., Liu, N., Wang, B., Feng, L., Fan, Z., Wang, L., Han, J., Zhang, X., Jin, H., Li, D., Liu, Y., Zuo, J., & Wang, Y. (2026). Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71885
Vancouver
Liu J, Liu X, Li X, Liu N, Wang B, Feng L, et al. Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71885
BibTeX
@article{Liu2026,
author = {Liu, Jiayin and Liu, Xun and Li, Xiaolin and Liu, Ning and Wang, Bo and Feng, Li and Fan, Zhisong and Wang, Long and Han, Jing and Zhang, Xue and Jin, Hui and Li, Dan and Liu, Yan and Zuo, Jing and Wang, Yudong},
title = {Identification of Prognostic Risk Factors in Older Patients With Extensive‐Stage Small Cell Lung Cancer},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71885}
}
EUVIMED